DNDanavath Nagendra

Danavath Nagendra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Danavath Nagendra has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interpretable prediction of mortality in zinc phosphide poisoning using combined statistical and machine learning models: a retrospective observational study

    by Thejesh Srinivas, Gagana Hanumaiah, Ashritha A. Udupa, Shruthi Rao, Souvik Chaudhuri, Shwethapriya R., Bharatkumar A. Patil, Danavath Nagendra, Vinutha R. Bhat

    Zinc phosphide poisoning is associated with high mortality due to rapidly evolving multi-organ dysfunction, yet reliable early risk stratification remains limited. This retrospective observational study evaluated the feasibility of combining conventional statistical modelling with interpretable machine learning (ML) for prediction of in-hospital mortality. A total of 290 adults with confirmed zinc phosphide poisoning admitted to a tertiary care hospital between January 2016 and November 2022 were included. In-hospital mortality occurred in 88 patients (30.3%). Demographic, physiological, and laboratory variables recorded within the first 48 h of hospitalization were analysed. Multivariable logistic regression was performed to identify independent predictors of mortality. Subsequently, ML models (logistic regression, Random Forest, and Extreme Gradient Boosting [XGBoost]) were developed using repeated stratified cross-validation, and model discrimination was assessed using the area under the receiver operating characteristic curve (AUROC), calibration analysis, and bootstrap-derived confidence intervals. Explainable artificial intelligence using SHapley Additive exPlanations (SHAP) was applied to the best-performing model. Serum lactate remained the only independent predictor of in-hospital mortality in the multivariable logistic regression analysis. Among the ML models, XGBoost achieved the highest numerical AUROC (0.745; 95% confidence interval, 0.680–0.807), although differences between models (DeLong’s test) were not statistically significant. SHAP analysis identified bicarbonate, lactate, potassium, creatinine, and activated partial thromboplastin time as the largest contributors to the mortality predictions generated by the optimized XGBoost model. These findings suggest that interpretable ML may complement conventional regression by providing transparent, individualized mortality prediction while preserving clinical interpretability. However, these exploratory findings require prospective multicentre validation before routine clinical implementation.

  • Open Access

    Systemic inflammation score, organ dysfunction and bacteraemia are independently associated with in-hospital mortality in critically ill patients with Klebsiella pneumoniae infection

    by Danavath Nagendra, Thejesh Srinivas, Asha K. Rajan, Souvik Chaudhuri, R. Neeraja, Gagana Hanumaiah, K. E. Vandana, Ancita Lobo, Muralidhar Varma, Vinutha R. Bhat

    Klebsiella pneumoniae is a major cause of severe infections among critically ill patients and is frequently associated with multidrug resistance (MDR). However, the relative prognostic importance of antimicrobial resistance, illness severity, bacteraemia, and Systemic Inflammation Score (SIS) remains incompletely understood. We evaluated the independent associations of organ dysfunction severity, bacteraemia, SIS, and MDR with in-hospital mortality among critically ill patients with microbiologically confirmed K. pneumoniae infection. This prospective observational study included 144 adult ICU patients with microbiologically confirmed monomicrobial K. pneumoniae infection. Clinical, laboratory, and microbiological variables were collected at the index infectious episode. Multivariable logistic regression was performed to identify variables independently associated with in-hospital mortality. Internal validation of the regression model was performed using 1,000 bootstrap resamples with bias-corrected and accelerated (BCa) confidence intervals. Exploratory machine learning analyses were performed using six supervised algorithms, and model interpretability was evaluated using Shapley Additive Explanations (SHAP). Overall in-hospital mortality was 52.8%. MDR and carbapenem-resistant isolates were identified in 67.4% and 54.9% of patients, respectively. In the primary multivariable model, SOFA score (adjusted odds ratio [aOR] 1.158, 95% confidence interval [CI] 1.071–1.252; p < 0.001), bacteraemia (aOR 3.609, 95% CI 1.504–8.657; p = 0.004), and SIS (aOR 3.260, 95% CI 1.241–8.565; p = 0.016) were independently associated with in-hospital mortality. Internal bootstrap validation using 1,000 resamples supported the robustness of the independent associations identified in the primary multivariable model (BCa 95% CIs: SOFA 1.06–1.31, bacteraemia 1.26–15.83, SIS 1.04–21.20). MDR was not independently associated with mortality after adjustment (aOR 1.352, 95% CI 0.396–4.615; p = 0.631). Among the exploratory machine learning models, Gaussian Naïve Bayes demonstrated the highest predictive performance (AUROC 0.78; Brier score 0.19). Global SHAP analysis ranked SOFA score, empirically active antimicrobial therapy, bacteraemia, and SIS as the most influential predictors within the prediction model. In this prospective observational cohort of critically ill patients with microbiologically confirmed K. pneumoniae infection, higher SOFA score, bacteraemia, and higher SIS were independently associated with in-hospital mortality, whereas MDR was not independently associated with mortality after multivariable adjustment, although this finding should be interpreted cautiously given the modest sample size and the wide confidence interval. The bootstrap analysis demonstrated the internal stability of the primary regression model. The exploratory machine learning analyses yielded predictor rankings broadly consistent with the regression findings but should be interpreted as complementary predictive analyses rather than evidence of causal or biological importance. External validation in independent cohorts is warranted before clinical implementation.

  • Open Access

    Immunometabolic reprogramming and mitochondrial dysfunction in acute respiratory distress syndrome: mechanisms, metabolic resilience, and therapeutic perspectives- a narrative review

    by Thejesh Srinivas, Gagana Hanumaiah, Danavath Nagendra, Shwethapriya R., Souvik Chaudhuri, Vinutha R. Bhat, Shobha U. Kamath

    Background: Acute respiratory distress syndrome (ARDS) is a biologically heterogeneous condition in which patients exposed to similar injurious stimuli often develop markedly different clinical trajectories and outcomes. While inflammation is central to ARDS pathogenesis, inflammatory burden alone does not fully explain the variability in disease progression, treatment response, or recovery. Emerging evidence suggests that immunometabolic reprogramming, characterized by increased glycolysis, impaired mitochondrial oxidative phosphorylation, and altered metabolite signalling, plays a critical role in shaping immune-cell activation, inflammatory persistence, and tissue repair during critical illness. Main body: This narrative review synthesizes current evidence linking immunometabolic reprogramming and mitochondrial dysfunction to the clinical heterogeneity observed in ARDS. During acute lung injury, immune and structural lung cells undergo metabolic shifts characterized by increased glycolysis, impaired mitochondrial oxidative phosphorylation, and accumulation of bioactive metabolites such as lactate, succinate, and extracellular adenosine triphosphate (ATP). Beyond reflecting metabolic stress, these metabolites function as signalling mediators that are associated with amplified inflammatory pathways, compromised alveolar-capillary barrier integrity, and sustained lung injury. Multi-omic studies further demonstrate that distinct metabolic signatures are associated with ARDS phenotypes, disease severity, and treatment responsiveness. We integrate these findings within the concept of metabolic resilience, defined as the host’s capacity to restore coordinated mitochondrial function, redox balance, and substrate utilization following inflammatory stress. Therapeutic strategies aimed at preserving mitochondrial function, restoring nicotinamide adenine dinucleotide (NAD⁺) homeostasis, and modulating maladaptive immunometabolic signalling may offer new avenues for precision-based interventions in ARDS. Conclusions: Immunometabolic reprogramming and mitochondrial dysfunction represent central biological axes linking cellular bioenergetics with clinical heterogeneity in ARDS. Understanding metabolic resilience may help refine phenotyping strategies and support development of metabolism-targeted therapies aimed at improving outcomes in this complex syndrome. Clinical trial number: Not applicable.


  • Open Access

    Rifampicin as an antivirulence adjunct in hypervirulent/hypermucoviscous Klebsiella pneumoniae infections: a scoping review

    by Danavath Nagendra, Asha K. Rajan, Thejesh Srinivas, Vandana K.E, Aruna Poojary, Abduallah Zaawari, Gagana Hanumaiah, Neeraja R, Ancita Lobo, Souvik Chaudhuri

    Background: Hypervirulent/Hypermucoviscous Klebsiella pneumoniae (HvKp/HmKp) is associated with invasive community-acquired infections and metastatic complications, with reports of clinical failure despite in vitro susceptibility to standard antibiotics. Rifampicin has been described in experimental settings to modulate virulence by suppressing the hypermucoviscous phenotype through RNA polymerase-dependent regulation of capsule-associated genes. This scoping review aimed to systematically map the available evidence evaluating rifampicin as a potential antivirulence adjunct in HvKp/HmKp infections. Methods: This scoping review was conducted in accordance with the Joanna Briggs Institute methodology and reported following the PRISMA-ScR guidelines. A structured search of PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library was performed from database inception to May 2026 using predefined terms related to hypervirulence, Klebsiella pneumoniae , and rifampicin/rifampin. The search was supplemented by grey literature and reference list screening. Studies evaluating rifampicin in phenotypically, genotypically, or syndromically defined HvKp were eligible, including experimental and clinical reports describing rifampicin as adjunctive or salvage therapy. Data were charted and synthesized narratively to map study characteristics, proposed mechanisms, and reported outcomes. Results: Of 1,361 records identified, 11 studies met the inclusion criteria, comprising four experimental/mechanistic studies, five full-text clinical case reports, and two conference abstracts. Experimental studies suggested that rifampicin may reduce hypermucoviscosity by suppressing capsule-associated pathways, particularly through the RpoB– rmpA axis, leading to reduced capsule thickness and downregulation of virulence-related genes. Additional preclinical studies showed enhanced activity when rifampicin was used in combination with zidovudine or the outer membrane-disrupting peptide SLAP-S25, with improved bacterial killing and survival in murine infection models. Clinical evidence was limited to case reports and conference abstracts in which rifampicin was used only as part of combination therapy for severe, disseminated, persistent, or difficult-to-treat HvKp/HmKp infections. Reported clinical outcomes were variable, and the independent contribution of rifampicin could not be determined. Conclusion: Current evidence suggests that rifampicin has biologically plausible antivirulence activity against HvKp/HmKp, mainly through suppression of capsule-associated hypermucoviscosity, and may have potential as an adjunct in selected severe or persistent infections. However, the available clinical evidence is sparse, uncontrolled, and heterogeneous. Rifampicin should therefore be considered hypothesis-generating rather than established therapy. Further mechanistic, pharmacokinetic, and prospective clinical studies are required to define its role, optimal combinations, dosing, safety, and clinical effectiveness in HvKp/HmKp infections.

  • Open Access

    Factors associated with severity in Klebsiella pneumoniae community-acquired pneumonia: A retrospective cohort study from South India

    by Souvik Chaudhuri, Tirlangi Praveen Kumar, Shreya Das Adhikari, Danavath Nagendra, Prithvishree Ravindra, Rachana Bhat, K.E. Vandana, Nitin Gupta

  • Open Access

    Definitional ambiguity and the dual threat of Hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis

    by Danavath Nagendra, Veena Suresh, Ashritha A. Udupa, Thejesh Srinivas, Vandana Kalwaje Eshwara, Muralidhar Varma, Prabha Prakash, Shruthi Rao, Souvik Chaudhuri

    Background: Hypervirulent Klebsiella pneumoniae (HvKp) causes severe invasive infections, but the lack of a standardized definition complicates surveillance. The emergence of carbapenem-resistant HvKp (CR-HvKp) poses a “dual-risk” threat whose impact is poorly quantified. This meta-analysis aimed to determine pooled proportions of severe outcomes stratified by diagnostic criteria and quantify the mortality risk associated with CR-HvKp. Methods: Following PRISMA guidelines, we systematically searched five databases for studies published up to July 2025 reporting clinical outcomes of HvKp infection. A random-effects model was used to calculate pooled proportions of liver abscess, metastatic spread, septic shock, microbiological failure and mortality, with subgroup analyses by HvKp definition (phenotypic, molecular, combined, or clinical). Odds ratios (OR) for mortality in CR-HvKp versus carbapenem-susceptible (CS)-HvKp were pooled. Results: From 4413 records, 79 studies involving 4240 patients were included. The pooled proportion of liver abscess was 24% (95% CI 17–32%) and metastatic spread was 22% (95% CI 12–32%), both significantly influenced by the diagnostic criteria used (p < 0.0001). Pooled mortality for HvKp was 21% (95% CI 15–27%). In stark contrast, pooled mortality for CR-HvKp was 57% (95% CI 35–78%). The frequency of microbiological failure among HvKp infected patients was reported to be 39%. A meta-analysis of six studies revealed CR-HvKp infection was associated with over 12-fold higher odds of death compared to CS-HvKp infection. Conclusion: HvKp continues to cause severe invasive infections, though outcome estimates vary due to inconsistent definitions. Mortality increases markedly when carbapenem resistance co-exists with virulence, indicating that poor outcomes are driven by both pathogenic and resistance mechanisms. Standardized diagnostic criteria and expanded genomic surveillance are essential to improve epidemiological comparability and guide early detection and containment of high-risk HvKp strains.


  • Open Access

    The utility of angiopoietin-2 and blood cell-derived biomarker indices in differentiating rapidly improving acute respiratory distress syndrome (RIARDS) phenotype from persistent-ARDS: a prospective observational study

    by Thejesh Srinivas, Vinutha R Bhat, Shwethapriya R, Pratibha Todur, Gagana Hanumaiah, Prithvishree Ravindra, Danavath Nagendra, Shobha U Kamath, Ashritha A Udupa, Shruthi Rao, et al.

    Rapidly improving acute respiratory distress syndrome (RIARDS) is defined as normalization of oxygenation (PaO2/FiO2 >300 mmHg) within 24 h of invasive mechanical ventilation. Angiopoietin-2 (Ang-2), a marker of endothelial dysfunction, may predict acute respiratory distress syndrome (ARDS) outcomes, but its role in RIARDS is unclear. This study evaluated Ang-2 and other biomarkers for predicting RIARDS and their association with survival. In this prospective observational study (June 2023-January 2025) at a 2032-bedded tertiary centre, 193 consecutively enrolled mechanically ventilated ARDS patients were assessed. Demographic, clinical, and laboratory data were recorded on Day 1. Plasma Ang-2 was measured using a high-sensitivity ELISA. Primary outcome was RIARDS; secondary outcome was ICU survival. RIARDS occurred in 18.6% of patients, highest in mild ARDS (52.9%) versus moderate (19.2%) and severe (10.4%). Multivariable regression identified Ang-2 as an independent predictor. A cut-off of 5896 pg/mL yielded an AUC of 0.731 (sensitivity 57.3%, specificity 88.9%). Patients with Ang-2 < 5896 pg/mL were more likely to develop RIARDS (86.1% vs. 13.9%, p-value < 0.001). Kaplan-Meier analysis showed significantly better ICU survival in RIARDS. Early Ang-2 measurement may help differentiate RIARDS from persistent ARDS, enabling prognostic enrichment and personalized management.

  • Open Access

    Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis

    by Ashritha A Udupa, Pratibha Todur, Souvik Chaudhuri, Nitin Gupta, Vinutha R Bhat, Danavath Nagendra, Shruthi Rao, Shwethapriya Rao, Prithvishree Ravindra, Thejesh Srinivas, et al.

    Acute respiratory distress syndrome (ARDS) is a life-threatening condition with a high mortality rate despite advances in supportive care. Aviptadil, a synthetic analogue of vasoactive intestinal peptide (VIP), exhibits anti-inflammatory potential and cytoprotective effects that may improve pulmonary function. However, its role in improving survival among ARDS patients remains uncertain. This systematic review and meta-analysis aimed to evaluate the effectiveness of aviptadil in improving survival and oxygenation outcomes in ARDS. A comprehensive search was conducted across six databases—PubMed, Scopus, Embase, Google Scholar, Cochrane Library, and Web of Science—up to October 2025. Two investigators independently screened eligible studies. Descriptive synthesis and meta-analysis were performed using a random-effects model. The risk of bias (RoB) was assessed with the RoB 2 tool for randomized controlled trials (RCTs) and the Joanna Briggs Institute (JBI) tool for case series. The systematic review included nine studies (two RCTs and seven case series) with a total of 665 patients, 361 of whom received aviptadil. Meta-analysis of the two RCTs yielded a pooled prevalence of survival of 0.71 [95% confidence interval (CI): 0.53–0.87]. The survival odds ratio (OR) comparing aviptadil to placebo was 1.01 (95% CI: 0.72–1.42, p = 0.93), indicating no significant benefit. Across the case series, 48 of 54 patients (88.9%) survived following aviptadil therapy, demonstrating consistent improvements in oxygenation and reductions in inflammatory markers. Aviptadil may have a physiological role in improving oxygenation and reducing inflammation in ARDS; however, current evidence does not indicate a significant survival benefit. Larger, well-designed RCTs are needed to clarify its therapeutic potential. Udupa AA, Todur P, Chaudhuri S, Gupta N, Bhat VR, Nagendra D, et al. Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis. Indian J Crit Care Med 2025;29(11):942–953.

  • Open Access

    Incidental detection of hypervirulent klebsiella pneumoniae liver abscess with systemic and cardiac complications in an elderly diabetic woman

    by Danavath Nagendra, Neeraja R, Vishal Shanbhag, Vandana Kalwaje Eshwara, Kusugodlu Ramamoorthi, Ps Priya, Ancita Lobo, Souvik Chaudhuri


  • Open Access

    Predictors of mortality in sepsis patients with Acinetobacter baumannii and Klebsiella pneumoniae bacteremia

    by Danavath Nagendra, Vandana Kalwaje Eshwara, Souvik Chaudhuri, Vishal Shanbhag, Thejesh Srinivas